Abstract: Provided are human polyclonal immunoglobulin products for use in treating or preventing coronavirus disease. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.

Abstract: A method for processing a silicon wafer, the method including cutting an ingot to form a wafer, extracting from measured shape data a cross-sectional profile, the cross-sectional profile passing through the center of the wafer and being aligned with a cutting direction of an ingot, interpolating the shape data with a fixed and pre-determined step size, fitting a first second-degree polynomial to the cross-sectional profile, determining a residual profile by subtracting the polynomial from the cross-sectional profile, fitting a second second-degree polynomial to the residual profile using a sliding window of pre-determined width to determine a position, height, and curvature of each peak and valley of the residual profile, determining a waviness parameter based on the position, height, and curvature of each peak and valley of the residual profile, and further processing the wafer based on the waviness parameter and a predetermined waviness threshold.

Abstract: The invention relates to the field of fuel cells, and in particular to a method for preparing highly stable catalyst coating slurry for fuel cells. The method for preparing highly stable catalyst coating slurry for fuel cells, includes at least two mixing and dispersing steps. The first mixing and dispersing step is carried out to mix and disperse the catalyst, perfluorosulfonic acid resin and solvent to obtain a first-stage mixed dispersion, and the other mixing and dispersing steps are carried out to mix and disperse the previous-stage mixed dispersion and the newly added perfluorosulfonic acid resin, wherein at least one mixing and dispersing step has a surfactant is added for mixing and dispersing. The catalyst in the catalyst slurry prepared by the method has good dispersion stability and less sedimentation, and good performance is achieved when the catalyst slurry is applied to membrane electrodes.

Abstract: A key management system includes secured data stored on a first system secured by a control key stored securely on a key server. The secured data is secured against attacks such as unauthorized use, modification or access, where authorization to access the secured data is determined by knowledge of an access private key of an access key pair. When an authorized user is to access the secured data, the first system generates a request to the key server, signed with the access private key, wherein the request is for a decryption control key and the request includes a one-time public key of a key pair generated by the first system for the request. The first system can decrypt the decryption control key from the response, using a one-time private key. The first system can then decrypt the secured data with the decryption control key remaining secured in transport.

Abstract: A key management system includes secured data stored on a first system secured by a control key stored securely on a key server. The secured data is secured against attacks such as unauthorized use, modification or access, where authorization to access the secured data is determined by knowledge of an access private key of an access key pair. When an authorized user is to access the secured data, the first system generates a request to the key server, signed with the access private key, wherein the request is for a decryption control key and the request includes a one-time public key of a key pair generated by the first system for the request. The first system can decrypt the decryption control key from the response, using a one-time private key. The first system can then decrypt the secured data with the decryption control key remaining secured in transport.

Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

Abstract: A key management system includes secured data stored on a first system secured by a control key stored securely on a key server. The secured data is secured against attacks such as unauthorized use, modification or access, where authorization to access the secured data is determined by knowledge of an access private key of an access key pair. When an authorized user is to access the secured data, the first system generates a request to the key server, signed with the access private key, wherein the request is for a decryption control key and the request includes a one-time public key of a key pair generated by the first system for the request. The first system can decrypt the decryption control key from the response, using a one-time private key. The first system can then decrypt the secured data with the decryption control key remaining secured in transport.

Abstract: A key management system includes secured data stored on a first system secured by a control key stored securely on a key server. The secured data is secured against attacks such as unauthorized use, modification or access, where authorization to access the secured data is determined by knowledge of an access private key of an access key pair. When an authorized user is to access the secured data, the first system generates a request to the key server, signed with the access private key, wherein the request is for a decryption control key and the request includes a one-time public key of a key pair generated by the first system for the request. The first system can decrypt the decryption control key from the response, using a one-time private key. The first system can then decrypt the secured data with the decryption control key remaining secured in transport.

Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

Abstract: Methods are provided for forming a circuit component on a workpiece substrate. The methods comprise the steps of depositing a dielectric material over the substrate; etching a pattern through the dielectric material to expose a portion of the substrate; depositing a barrier metal over the dielectric material and the exposed portion of the substrate; depositing a conductive metal over the barrier metal, the deposited conductive metal having a thickness sufficient to fill the etched pattern; planarizing the conductive metal to form a planar metal layer; and polishing the metal layer and the barrier metal in a single polishing step using an abrasive-free polish until the dielectric material surrounding the pattern is exposed.

Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

Abstract: The invention provides a novel class of compounds and compositions of Formula I: in which R1, R2 and R3 are defined herein, that are useful in the treatment or prevention of diseases or disorders associated with kinases, particularly GSK-3?, c-Abl, HER-1, HER-2, KDR, Flt-3, c-Raf-1, PDGFR-?, c-Kit, Flt-4, Flt-1, Tek, c-src, CDK1, PDK1, FGFR-1, FGFR-2, Fer, MAP3K13, EPHA7 and c-Met kinases. The invention further relates to the use of the compounds of the invention as potent inducers of neurogenesis in embryonic stem cells.

Abstract: Methods are provided for forming a circuit component on a workpiece substrate. The methods comprise the steps of depositing a dielectric material over the substrate; etching a pattern through the dielectric material to expose a portion of the substrate; depositing a barrier metal over the dielectric material and the exposed portion of the substrate; depositing a conductive metal over the barrier metal, the deposited conductive metal having a thickness sufficient to fill the etched pattern; planarizing the conductive metal to form a planar metal layer; and polishing the metal layer and the barrier metal in a single polishing step using an abrasive-free polish until the dielectric material surrounding the pattern is exposed.

Abstract: Methods are provided for forming a circuit component on a workpiece substrate. The methods comprise the steps of depositing a dielectric material over the substrate; etching a pattern through the dielectric material to expose a portion of the substrate; depositing a barrier metal over the dielectric material and the exposed portion of the substrate; depositing a conductive metal over the barrier metal, the deposited conductive metal having a thickness sufficient to fill the etched pattern; planarizing the conductive metal to form a planar metal layer; and polishing the metal layer and the barrier metal in a single polishing step using an abrasive-free polish until the dielectric material surrounding the pattern is exposed.

Abstract: Methods are provided for forming a circuit component on a workpiece substrate. The methods comprise the steps of depositing a dielectric material over the substrate; etching a pattern through the dielectric material to expose a portion of the substrate; depositing a barrier metal over the dielectric material and the exposed portion of the substrate; depositing a conductive metal over the barrier metal, the deposited conductive metal having a thickness sufficient to fill the etched pattern; planarizing the conductive metal to form a planar metal layer; and polishing the metal layer and the barrier metal in a single polishing step using an abrasive-free polish until the dielectric material surrounding the pattern is exposed.

Abstract: The invention provides a novel class of compounds and compositions that are useful in the treatment or prevention of diseases or disorders associated with kinases, particularly GSK-3?, c-Abl, HER-1, HER-2, KDR, Flt-3, c-Raf-1, PDGFR-?, c-Kit, Flt-4, Flt-1, Tek, c-src, CDK1, PDK1, FGFR-1, FGFR-2, Fer, MAP3K13, EPHA7 and c-Met kinases. The invention further relates to the use of the compounds of the invention as potent inducers of neurogenesis in embryonic stem cells.

Abstract: A key management system includes secured data stored on a first system secured by a control key stored securely on a key server. The secured data is secured against attacks such as unauthorized use, modification or access, where authorization to access the secured data is determined by knowledge of an access private key of an access key pair. When an authorized user is to access the secured data, the first system generates a request to the key server, signed with the access private key, wherein the request is for a decryption control key and the request includes a one-time public key of a key pair generated by the first system for the request. The first system can decrypt the decryption control key from the response, using a one-time private key. The first system can then decrypt the secured data with the decryption control key remaining secured in transport.